NASDAQ OMX

Sobi får kommersialiseringsrättigheter för Relistor®, Deflux® och Solesta® av PharmaSwiss

7.1.2016 08:00 | NASDAQ OMX

Dela

Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) offentliggjorde idag att bolaget erhållit kommersialiseringsrättigheter från det Schweiziska bolaget PharmaSwiss för att distribuera Relistor®, Deflux® och Solesta® i stora delar av Europa inklusive Västeuropa, Tjeckien, Slovakien och Ungern, samt för Relistor även Ryssland.

"Jag är glad över att vi nu utökar vårt framgångsrika samarbete med PharmaSwiss och att vi kan erbjuda patienter och läkare flera behandlingsalternativ som adresserar stora medicinska behov inom varje specifikt terapiområde", säger Alan Raffensperger, senior vice president och Chief Operating Officer vid Sobi.

Sobi kommer att hantera all kommersiell verksamhet inom området, vilket också inkluderar lansering, tillgång till produkt för marknaden och för patienter, samt marknadsföringsaktiviteter, medan PharmaSwiss kommer fortfarande att ansvara för tillverkningen och tillhandahålla de färdiga produkterna samt produktinformation.

De tre nya produkterna som Sobi kommer att distribuera, varav ett är läkemedel och två är medicintekniska produkter, är godkända för specialistindikationer:

  • Relistor (metylnaltrexonbromid) är indicerat för behandling av opioidframkallad förstoppning när behandling med laxermedel hos vuxna patienter i åldern 18 år och äldre inte varit tillräcklig
  • Deflux är indicerat för behandling av barn med vesikoureteral reflux
  • Solesta är indicerat för behandling av fekal inkontinens hos patienter i åldern 18 år och äldre som inte svarat på standardbehandling

 

I juni 2013 offentliggjorde Sobi sitt första distributionsavtal med PharmaSwiss för marknadsföring av Megace®, Monopril®, Cefzil® and Duricef®, produkter som är godkända för behandling inom följande terapiområden; onkologi, kardiovaskulär sjukdom och infektionssjukdomar.

----

Om Sobi Partner Products
Sobi Partner Products (SPP) är en affärsenhet inom Sobi som erbjuder en unik kommersialiseringsplattform för partners med nisch- och specialprodukter. SPP erbjuder omfattande kunskaper och lokal erfarenhet genom vår direkta närvaro över hela EU, Östeuropa, Ryssland, Mellanöstern och Nordafrika. Vi tillämpar ett integrerat kommersiellt, medicinskt och marknadstillgångsförhållningssätt för produkter som möter viktiga otillfredsställda behov, från enskilda licensprogram till subventionering och full kommersialisering, främst inom våra kompetensområden 

Om Sobi
Sobi är ett internationellt läkemedelsföretag inriktat på att tillhandahålla innovativa behandlingar och service som förbättrar livet för patienter med sällsynta sjukdomar. Produktportföljen fokuserar främst på hemofili, inflammationssjukdomar och genetiska sjukdomar. Sobi marknadsför även en portfölj specialist- och särläkemedel på uppdrag av olika partnerföretag i Europa, Mellanöstern, Ryssland och Nordafrika. Intäkterna uppgick 2014 till 2,6 miljarder kronor och antalet anställda var cirka 600. Aktien (STO: SOBI) är noterad på OMX NASDAQ Stockholm. Ytterligare information finns på www.sobi.com.

För ytterligare information kontakta

Media relations  Investor relations
Charlotte af Klercker, Corporate Communications Jörgen Winroth, Vice President, Head of Investor Relations
T: +46 70 729 7327 T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135
charlotte.afklercker@sobi.com jorgen.winroth@sobi.com

 




This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Globenewswire

HUG#1976117

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.

Senaste pressmeddelandena från NASDAQ OMX

Promethean Opens New Global Headquarters in Seattle18.8.2017 18:38Pressmeddelande

Seattle, Wash., Aug. 18, 2017 (GLOBE NEWSWIRE) -- PrometheanTM, a global education technology company, announced today the opening of its new global headquarters in Seattle, Wash. Promethean's office in Atlanta, Ga. will continue to serve as the hub for the Americas markets, and the Blackburn, U.K. office will continue to carry on as the hub for the EMEA markets and parts of Asia.  Promethean is one of the leading brands in the international education technology market with more than 20 years of experience in the K-12 classroom. Its solutions are in more than 50,000 schools and institutions in 154 countries. "As traditional pedagogy continues to move towards immersive learning, it's important for Promethean to lead innovation in education with the latest technology," said Vin Riera, CEO of Promethean. "Seattle is a global technology hub, and establishing Promethean's global headquarters there increases opportunities for new business models, concepts

Hminers Disrupts the Cryptocurrency Market with Powerful, Multi-Algorithm Mining Rigs18.8.2017 11:00Pressmeddelande

Hminers continues to hit the headlines in the rapidly expanding global market for cryptocurrency. The Miami-based company has recently introduced three extremely powerful, multi-algorithm mining rigs that have been designed to provide maximum hash rate with minimum power consumption. MIAMI, Aug. 18, 2017 (GLOBE NEWSWIRE) -- In their relentless efforts to deliver state-of-the-art products related to cryptocurrency, Hminers has recently launched three brilliantly designed bitcoin mining rigs. The unique features and capabilities of the company's new H2U Miner, H4U Miner, and Rack Equipped with 5 x H4U have already grabbed the attention of the cryptocurrency enthusiasts and experts around the world. An organization with a rich tradition, Hminers (www.hminers.com) is recognized in the industry as the creator of the first ever 10 nm ASIC Chip in the world. Cryptocurrency mining is the process of generating new cryptocurrency that requires a pot

Nasdaq Welcomes I-AM Capital Acquisition Company (Nasdaq: IAMXU) to The Nasdaq Stock Market17.8.2017 18:50Pressmeddelande

NEW YORK, Aug. 17, 2017 (GLOBE NEWSWIRE) -- I-AM Capital Acquisition Company (Nasdaq:IAMXU), a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, celebrated its initial public offering (IPO) on The Nasdaq Stock Market.  I-AM Capital's founders, Chief Executive Officer F. Jacob Cherian and Chief Financial Officer Suhel Kanuga, have been focused on investing into India over the last decade, with the distinction of completing the first listed-SPAC investment in India. "Through our keen focus and unique accomplishments in India over the last decade, we have seen our investment thesis bear fruit: India's prominence and rise on the world stage, its distinction as being one of the fastest growing major economies of the world, and its strong vibrant consumer demographics. We believe these factors are aligning well now,

Tetraphase Pharmaceuticals Announces Submission and Validation of IV Eravacycline Marketing Authorization Application by European Medicines Agency17.8.2017 14:30Pressmeddelande

WATERTOWN, Mass., Aug. 17, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug- resistant (MDR) infections, today announced that the Marketing Authorization Application (MAA) for IV eravacycline for the treatment of complicated intra-abdominal infections (cIAI) has been submitted and was validated by the European Medicines Agency (EMA). Eravacycline is a novel, fully-synthetic fluorocycline antibiotic being developed for the treatment of serious infections, including those caused by multidrug-resistant (MDR) pathogens. The MAA filing is based on data from the phase 3 IGNITE1 clinical trial in which eravacycline was well tolerated and demonstrated statistical non-inferiority to ertapenem using the primary endpoint of clinical response at the test-of-cure (TOC) visit. "The MAA filing represents a significant milestone for Tetraphase as it is our

RedHill Biopharma Announces U.S. Commercialization Agreement for FDA-Approved GI Product Esomeprazole Strontium Delayed-Release Capsules17.8.2017 13:00Pressmeddelande

RedHill was granted the exclusive rights to promote Esomeprazole Strontium Delayed-Release (DR) Capsules to gastroenterologists in certain U.S. territories Esomeprazole Strontium DR Capsules 49.3 mg is an FDA-approved, proprietary, prescription proton pump inhibitor (PPI), indicated for adults for the treatment of gastroesophageal reflux disease (GERD) and other gastrointestinal (GI) conditions   RedHill expects to initiate the U.S. promotion of Esomeprazole Strontium  DR Capsules 49.3 mg  in the coming weeks   Esomeprazole Strontium  DR Capsules 49.3 mg  will be the third commercial GI product to be promoted by RedHill in the U.S.    RedHill's GI-focused sales force currently promotes two GI s

Brand Industrial Services Announces Agreement to Acquire Venko Groep BV16.8.2017 19:40Pressmeddelande

Complementary core strengths provide broader range of services for customers KENNESAW, GA, Aug. 16, 2017 (GLOBE NEWSWIRE) -- Brand Industrial Services, known as BrandSafway, has signed an agreement to acquire Venko Groep BV, a portfolio company of Mentha Capital. Venko will become a part of the Brand Energy & Infrastructure Services (Brand) group. "We are very pleased to announce the agreement with Venko," said Bill Hayes, President and CEO of BrandSafway. "Our combined customers in Europe will benefit from a broader range of solutions and greater depth of expertise in access, insulation and coatings. Bringing Venko's highly specialized knowledge in coatings to BrandSafway will provide the expertise we need to expand our services in the offshore market worldwide." Based in the Netherlands, with a focus on operations in the North Sea area, Venko is a leading offshore and onshore coatings maintenance provid

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum